A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors

Trial Profile

A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs MEDI 4276 (Primary)
  • Indications Breast cancer; Gastric cancer; Male breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 07 Mar 2018 Updated results will be presented at the conference (16th International Congress on Targeted Anticancer Therapies).
    • 07 Mar 2018 Results (n=43) assessing safety and efficacy presented at the 16th International Congress on Targeted Anticancer Therapies
    • 22 Jan 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top